Company Filing History:
2 out of 1,210 
2 out of 389 
1 out of 1,373 
Years Active: 2008-2010
Title: Innovations in Immunotherapy: The Contributions of Irene Chernova
Introduction: Irene Chernova, based in Brighton, MA, is a prominent inventor with a significant focus on immunotherapy. With two patents to her name, her work centers around enhancing immune responses, specifically targeting the interaction between PD-L2 and PD-1, a crucial area of research in cancer treatment.
Latest Patents: Irene’s latest patents encompass revolutionary methodologies for upregulating immune responses. One patent details methods for promoting or inhibiting the interaction between PD-L2 and PD-1, providing isolated nucleic acid molecules that encode novel B7-related molecules serving as ligands for PD-1. This invention also includes antisense nucleic acids, recombinant expression vectors, host cells, and nonhuman transgenic animals with modified PD-L2 genes. Additionally, various therapeutic applications such as diagnostic methods and treatments are encompassed in her inventions. Another patent focuses on identifying compounds that can enhance T cell activation in the presence of a PD-1 mediated signal, offering further insights into immune modulation.
Career Highlights: Irene has worked with distinguished organizations such as the Dana-Farber Cancer Institute and the Genetics Institute. Her tenure at these institutions has facilitated her innovative research and development in the field of immunology, aiding in the fight against cancer and other immune-related diseases.
Collaborations: Throughout her career, Irene Chernova has collaborated with talented individuals, including Tatyana Chernova and Nelly Malenkovich. These partnerships have enabled her to blend expertise and foster an environment conducive to cutting-edge discoveries in immunotherapy.
Conclusion: Irene Chernova stands as a testament to the potential of innovation in the realm of medical science. Her contributions to understanding and manipulating immune responses represent a pivotal advancement in therapeutic applications. Through her patents and collaborations, she is paving the way for new methodologies that could significantly improve cancer treatment outcomes.